Overview of Emerging Cannabinoids

Updated: Mar 11

Cannabis consumers and patients and the businesses that serve them remain challenged by a generalized ignorance of the chemical dynamics and market potential of a number of mainstream cannabinoids—primarily CBD (cannabidiol) and delta-9 THC (tetrahydrocannabinol).


Amidst a storm of misinformation has emerged a range of commercially novel molecules, making a clear understanding of their nuanced differences even more difficult.

Copyright © Higher Learning LV™


While considered new, many of these cannabinoids have been under scientific investigation for decades (for example, the U.S. military experimented with THC-O in the late 1940s). The beginning of the third decade of the 21st century has featured many forms of cultural and business disruption, including the emergence of these isomer molecules in both legal and underground markets throughout the United States.


These cannabinoids include CBDP, delta-8 THC, delta-10 THC, HHC (hexahydrocannabinol), THC-O Acetate, and THCP (links to our exclusive Knowledgebase articles appear below).


Confounding Marketers + Regulators

Lawmakers, regulators, entrepreneurs, and consumers have been forced to comprehend this confusing array of cannabinoids and the sometimes spurious marketing claims that accompany their distribution and sales.


Higher Learning LV has focused on the commerce+chemistry of these phytomolecules, some of which are naturally occurring (such as delta-8 and HHC) and some of which are not (including delta-10 and THC-O Acetate).

Higher Learning LV has focused on the commerce+chemistry of these phytomolecules, some of which are naturally occurring (such as delta-8 and HHC) and some of which are not (including delta-10 and THC-O Acetate).


New Research

In December 2019, a group of Italian researchers released a study that detailed its discovery of two novel cannabinoids, CBDP and THCP. Both are members of a new group of cannabinoids called phorals that feature a significantly stronger binding affinity within the human endocannabinoid system than conventional delta-9 THC. It remains to be seen if this stronger cellular connection equates to greater potency or enhanced efficacy among real world consumers.


The emergence of these phytomolecules is evidence that the future legal cannabis marketplace holds the potential to encompass and monetize a range of molecules outside of CBD and delta-9 THC. It also serves as a testimonial to the plant's significant overall efficacy, which some medical professionals have dubbed "a pharmacopeia."

Copyright © Higher Learning LV™


Research for these THC isomer molecules is, unfortunately, relatively scant compared to what is available for mainstream cannabinoids such as CBD, delta-9 THC, and a range of terpenes (like pinene, myrcene, and humulene). Several of these emerging cannabinoids have demonstrated medicinal efficacy, including anti-inflammatory, anticancer, and antianxiety properties, as evidenced by literally hundreds of peer-reviewed research studies.


To learn more about these molecules and their commercial and biochemical potential, we have compiled a list of our ten most popular Knowledgebase articles about them.

  1. Addressing the Delta-8 Controversy: https://bit.ly/31kvaeI

  2. C3 S1E5: Dr. Ben Caplan on Delta-8: https://bit.ly/3G58G0x

  3. Deep Dive: Newly Discovered Cannabinoids: THCP & CBDP: https://bit.ly/3EiRPqw

  4. Delta-8 THC Deep Dive: https://bit.ly/3d87v3M

  5. Hexahydrocannabinol (HHC): https://bit.ly/31elNxf

  6. Leafreport Delta-8 Market Survey: https://bit.ly/3lqlxm8

  7. Quick Read: Delta-8 THC: https://bit.ly/3G30FJs

  8. Quick Read: New Cannabinoids CBDP + THCP: https://bit.ly/3d7naQT

  9. Quick Read: THC-O: https://bit.ly/3IbyolS

  10. Quick Read: What is Delta-10 THC?: https://bit.ly/3DbFOSn

Learn More

To learn more, subscribe to the Higher Learning LV™ Knowledgebase, the largest ad-free cannabis article/video repository in the world!

367 views0 comments

Recent Posts

See All